We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

99 hedge funds and large institutions have $100M invested in Enzo Biochem, Inc. in 2016 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 10

60% more call options, than puts

Call options by funds: $481K | Put options by funds: $300K

21% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 24

11% more funds holding

Funds holding: 8999 (+10)

7% more capital invested

Capital invested by funds: $93.6M → $100M (+$6.41M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
99
Holders Change
+10
Holders Change %
+11.24%
% of All Funds
2.64%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
20
Increased
29
Reduced
24
Closed
10
Calls
$481K
Puts
$300K
Net Calls
+$181K
Net Calls Change
+$179K
Name Holding Trade Value Shares
Change
Change in
Stake
RFC
26
Russell Frank Company
Washington
$485K +$273K +61,368 +136%
CCM
27
Corsair Capital Management
New York
$454K -$22.5K -5,065 -5%
Deutsche Bank
28
Deutsche Bank
Germany
$450K +$89.3K +20,061 +25%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$449K
Northern Trust
30
Northern Trust
Illinois
$422K -$22.4K -5,042 -5%
CS
31
Credit Suisse
Switzerland
$414K +$263K +58,980 +184%
Two Sigma Investments
32
Two Sigma Investments
New York
$412K +$69.1K +15,531 +21%
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$411K +$169K +37,908 +72%
BFA
34
BlackRock Fund Advisors
California
$402K -$29.3K -6,574 -7%
Citadel Advisors
35
Citadel Advisors
Florida
$346K +$77.7K +17,452 +30%
KCM
36
Kempner Capital Management
Texas
$319K
BCM
37
Breithorn Capital Management
New York
$288K -$633K -142,152 -69%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$288K +$191K +42,900 +209%
AIM
39
Acrospire Investment Management
Illinois
$273K +$268K +60,106 New
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$259K
SCM
41
Segantii Capital Management
Hong Kong
$256K +$258K +57,864 New
Barclays
42
Barclays
United Kingdom
$237K +$264K +59,236 +92,556%
Arrowstreet Capital
43
Arrowstreet Capital
Massachusetts
$227K +$222K +49,900 New
SIM
44
Spark Investment Management
New York
$211K
JP Morgan Chase
45
JP Morgan Chase
New York
$206K +$201K +45,167 New
Charles Schwab
46
Charles Schwab
California
$201K
PPA
47
Parametric Portfolio Associates
Washington
$153K +$150K +33,696 New
PAM
48
Panagora Asset Management
Massachusetts
$145K +$64K +14,383 +82%
Asset Management One
49
Asset Management One
Japan
$134K +$131K +29,366 New
LCM
50
Leisure Capital Management
California
$129K -$36.9K -8,300 -23%

ENZ Hedge Fund Activity: Q1 2016 in Review

99 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q1 2016, worth a combined $100M — up 6.8% from $93.6M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ENZ positions and 10 closed out — a net gain of 10 holders — while 29 added to existing stakes and 24 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $3.47M. The largest seller was First Light Asset Management, cutting an estimated $2.48M.

  • 99 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q1 2016, up from 89 in Q4 2015.
  • Funds reported $100M of Enzo Biochem, Inc. stock for Q1 2016, up 6.8% quarter-over-quarter.
  • 20 funds opened new Enzo Biochem, Inc. positions in Q1 2016 and 10 closed out, a net change of +10 holders.
  • The largest Enzo Biochem, Inc. buyer in Q1 2016 was Acadian Asset Management, an estimated $3.47M added.
  • The largest Enzo Biochem, Inc. seller in Q1 2016 was First Light Asset Management, an estimated $2.48M sold.

Based on aggregated 13F filings for Q1 2016.